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ABSTRACT 
Background: Oral Viscous Budesonide (OVB) is a recent therapeutic option for Eosinophilic 
Oesophagitis (EoE) versus dietary restriction and inhaled steroids. This single center, open label, 
not blinded study aims to evaluate the efficacy and safety of a new, pre-prepared oral viscous 
budesonide suspension (PVB) in children and adolescents with EoE. 
Methods: We treated with PVB 36 children (29 male; median age 12 years) with EoE diagnosed 
according to ESPGHAN guidelines. Patients <150 cm and >150 cm height received 2 mg and 4 mg 
PVB daily, respectively, for 12 weeks. Upper GI endoscopy was performed at baseline, after 12 
weeks of therapy and 24 weeks after the end of therapy. Baseline and post-treatment scores were 
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calculated for symptoms, endoscopy and histology. Serum cortisol was performed at baseline, 12, 
36 weeks.  
Results: At the end of PVB trial, endoscopy showed macroscopic remission in 32 patients (88,9%), 
while at histology median pre- and post-treatment peak eosinophil count/HPF markedly decreased 
from 42.2 (range: 15-100) to 2.9 (range: 0-30); moreover, mean symptom and histology scores 
impressively improved vs baseline (p<0.01). At 24 weeks after the end of PVB therapy, endoscopy 
showed oesophageal relapse in 21 patients (58,3%), whereas 15 (41,7%) were still in remission. 
Seven children (19,4%) with positive MII-pH were treated also with proton pump inhibitors.  No 
significant difference between pre-/post treatment morning cortisol levels occurred. 
Conclusions: the new PVB suspension presented in this study is effective and safe for treating 
children with proven EoE. Larger placebo controlled clinical trials would provide more information 
about dosing, efficacy, and long-term safety of this formulation, specifically designed for the 
oesophagus. 
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WHAT IS KNOWN 
 Topical steroids are the mainstay of Eosinophilic Oesophagitis (EoE) treatment in children 
and adults for many cases. 
 There is presently no topical steroid designed for oesophageal drug therapy. 
 Oral viscous budesonide (OVB) is actually considered more effective and is usually 
preferred to nebulized suspension, due to the higher esophageal mucosal contact time. 
WHAT IS NEW 
 This study showed that a new pre-prepared OVB (PVB) suspension is an effective and safe 
treatment for children with proven EoE. 
 PVB may have advantages over other therapies in that it is palatable, practical to use, and its 
volume provides pan-oesophageal mucosal coverage. 
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INTRODUCTION 
Eosinophilic oesophagitis (EoE) is defined as a chronic, immune/antigen-mediated oesophageal 
disease characterized clinically by symptoms related to oesophageal dysfunction and histologically 
by eosinophil-predominant inflammation (1). The exact incidence of EoE is not yet known, 
however, since 2000 it has become exponentially more prevalent in western countries, with a yearly 
incidence now considered to be similar to that of Crohn’s disease (2-3).  
EoE is more commonly seen in male patients and in patients with atopic diseases such as food 
allergy, asthma, and allergic rhinitis. Clinical symptoms vary according to age, ranging from food 
refusal and emesis to dysphagia and food impaction (4).  
Oral steroids are very effective in quickly resolving the eosinophilic oesophageal inflammation; 
however, because EoE is most likely a chronic disease, oral steroids are not indicated in daily 
management and should be reserved only for emergency, such as severe dysphagia, hospitalization, 
and weight loss (5). 
Swallowed inhaled corticosteroids such as swallowed fluticasone or budesonide have low 
bioavailability, less potential for systemic side effects, and are considered topical agents. They can 
improve quality of life, decrease inflammation, and induce EoE remission in up to 90% of patients 
depending on the different studies (6). 
Actually, the new clinical guidelines from the European Society for Paediatric Gastroenterology 
Hepatology and Nutrition (ESPGHAN) recommend topical corticosteroids and/or elimination diets 
as first-line pharmacologic treatment (7). However, despite the optimal results of dietary treatment, 
the latter may be limited by several drawbacks, such as severe food restriction and low compliance. 
Thus, topical steroids are the mainstay of EoE treatment in children and adults for many cases (8). 
Unfortunately, there is presently no topical steroid designed for oesophageal drug therapy, and 
options are limited to off-label administering of swallowed aerosolized or nebulized corticosteroid 
formulations that are designed for asthma. Budesonide is much easier to administer and was first 
used in children (9). The compound is bitter and often mixed with a sweetener, such as sucralose, 
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chocolate syrup, honey, to make a slurry called “oral viscous budesonide” (OVB). Despite, families 
are often exhausted of the use of artificial sweetener in high doses for their children (10), OVB is 
actually considered more effective and is usually preferred to nebulized suspension, due to the 
higher esophageal mucosal contact time (11). The suggested dose in children is 1 mg/day, and 2 
mg/day in divided doses for adults, but the optimal dosage has not formally assessed (12).  
Since there is not yet available any specific suspension of OVB, this pilot, single center, open label, 
not blinded study aims at evaluating the efficacy and safety of a new, proprietary, pre-prepared 
suspension of OVB (PVB), made by ITC Farma (Pomezia, Italy) in children and adolescents with 
proven EoE.  
 
PATIENTS AND METHODS 
Patients. Eligible patients were recruited at the Paediatric Gastroenterology and Liver Unit of the 
Sapienza University of Rome during 12 months (between January 2014 and February 2015). This 
Unit is a tertiary referral paediatric center for eosinophilic disorders. We prospectively enrolled 36 
consecutive paediatric subjects with a new or established diagnosis of EoE. Inclusion criteria were: 
age < 18 years; diagnosis of EoE with > 15 eosinophils/HPF in oesophageal biopsies after a PPI 
trial of at least 8 weeks (7); requesting alternatives to diet for new diagnosis, or a different 
pharmacologic treatment during an histological flare (in case of previous diet treatment and/or 
nebulized or systemic steroids). Exclusion criteria were: presence of non-EoE gastrointestinal 
diseases (eosinophilic gastroenteritis/colitis, IBD, or celiac disease); oesophageal stricture on 
baseline endoscopy that precluded passage of an upper scope; use of steroids (topical or systemic) 
within 4 weeks of the baseline endoscopy; change in dosing regimen of PPIs, diet, allergy 
medications, or inhaled steroids during the study period. Written informed consent was obtained 
from parents of all children; children over 12 years of age signed a statement of assent. 
An allergy assessment (through skin prick test, atopy patch test and specific IgE tests) was 
performed in all patients before the enrolment. A 24 hours pH multichannel intraluminal impedance 
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(MII-pH) was also executed during the screening period (or before an 8-week PPI therapy for new 
diagnosis) in order to minimize the potential for GERD to be the cause of oesophageal eosinophilia 
in case of positive results. According to the ESPGHAN guidelines, the following pH-MII variables 
were analyzed: occurrence both of acid (defined as a drop in pH < 4.0), and non-acid (defined as a 
drop in pH > 7.0) GER events; total exposure acid time (% of GER); the total number of acid and 
non-acid GER events; the long-lasting number of acid GER events; the symptomatic index (SI), that 
is the percentage of symptoms attributable both to acid (SI-A) and non-acid (SI-NA) GER. An 
exam was considered positive only if at least ≥ 3 of variables reported above were positive. Patients 
with a positive MII-pH continued a concurrent therapy with PPI (after the PPI test of 8 weeks) at 
dose of 1.0 mg/kg/day along the study. All authors have accessed to the study data, and have 
reviewed and approved the final manuscript. The study protocol was defined in accordance with the 
Declaration of Helsinki and approved by the ethical committee of the University Hospital Umberto 
I in Rome. 
Treatment. PVB is a galenic, pre-prepared formulation of budesonide, mainly mixed with xylitol, 
at concentration of 0.2 mg/mL, made by ITC Farma Srl (Pomezia, Italy), who provided the entire 
drug supply. Study participants were divided according to their height. Patients <150 cm and >150 
cm height received 1mg/5ml bid (2 mg/daily) and 2mg/10ml (4 mg/daily), respectively, for 12 
weeks. Morning and evening doses were administered after breakfast and at bedtime, respectively. 
The appropriate dose has been provided by using a capacity syringe. After the administration the 
bottle could be conserved at room temperature (no > 35°C or < 4°C). Subjects were instructed not 
to eat, drink, rinse their mouth, or brush their teeth for 30 minutes after taking study medication. 
Patients were clinically monitored at 6-week intervals and had access to a physician throughout 
their participation in the study to assist with any issues regarding the trial. Study medication 
adherence were also evaluated at each study visit by assessing the volume of medication remaining 
in each bottle to determine the approximate amount that has been taken since the prior visit. 
Adherence was calculated by dividing the amount of medication taken by the amount that should 
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have been taken, multiplied by 100. Subjects were considered adherent if they have received 
between 80% and 120% of the expected amount of medication.  
Clinical symptom score. Patients were clinically evaluated at 6-week intervals in our unit. Clinical 
presentation was evaluated at baseline, 12 and 36 weeks, with a clinical score that considered seven 
variables:  regurgitation/heartburn, abdominal pain, nausea/vomiting, anorexia/early satiety, 
dysphagia/food impaction, symptom induced nocturnal wakening, gastrointestinal bleeding; each 
symptom category were scored from 0 to 2 for intensity and frequency (13), for a total score from 0 
to 14 (Table 1).  
Endoscopy and histology. Endoscopy was performed at baseline, 12 and 36 weeks (6 months after 
the end of treatment) by the same board-certified gastroenterologist (SO), using conscious sedation, 
deep sedation or general anaesthesia (according with the different ages) (Figure 1). Endoscopic 
alterations were evaluated with an endoscopic score that considered presence of five characteristics: 
mucosal pallor, linear furrows/mucosal thickening, white plaques, friability and concentric rings or 
strictures; endoscopic score ranged from 0 to 5 for each oesophageal segment (maximum total score 
15 pts) (13). At the inclusion/T0 endoscopy, all subjects received oesophageal, gastric, and 
duodenal biopsies. At least 2 mucosal pinch biopsies were obtained from the proximal, mid, and 
distal oesophagus. Subjects with peak intraepithelial eosinophil counts of ≥15/HPF and no 
significant gastric or duodenal pathology were histologically eligible for the study. At the end of 
study endoscopy, at least 2 biopsies from all 3 oesophageal levels were performed in all subjects, 
while gastric and duodenal biopsies were performed at the physician’s discretion. Proximal, mid, 
and distal oesophageal biopsies, taken before and after treatment, were processed routinely and 
evaluated using light microscopy by an expert pathologist (AT). Two biopsies per level (proximal, 
mid and distal) yielded between 15 and 20 evaluable hps. A peak eosinophil count/HPF was 
obtained for each esophageal level by counting the number of eosinophils in the most inflamed area 
by using a Nikon Eclipse E400 (Nikon, Tokyo, Japan) light microscope at x 400 magnification (0.3 
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mm 2 HPF). Histological findings were scored with values of peak intraepithelial eosinophils count 
and other mucosal alterations characteristics of EoE (13); with a totally score from 0 to 18. 
Outcomes measures. The primary outcome measure was the improvement of oesophageal 
eosinophilia. The response to therapy was determined by comparing baseline and final treatment 
peak/counts/hpf under light microscopy (x400). Patients were categorized into responders (0-6 
eos/hpf), partial responders (7-19 eos/hpf), and non-responders ( 20 eos/hpf) based on final 
treatment biopsy results. Secondary outcomes included response in symptom, endoscopy and 
histology scores at the end of treatment.  
Safety assessment. Safety assessment included adverse event monitoring during the treatment; 
physical examination; height; weight; vital signs (heart rate, blood pressure); and laboratory tests 
(complete blood count with differential, serum glucose, morning serum cortisol). Clinical 
evaluations were assessed at baseline, at 6 and 12 weeks of treatment, while laboratory tests at 
baseline and 12 weeks only (Figure 1). Baseline and post-treatment morning cortisol levels were 
measured to estimate adrenal suppression of the PVB suspension. The cortisol was measured during 
other laboratory tests. 
Statistical analysis. All statistical analysis was carried out using the SPSS (SPSS 17.0 Chicago, 
USA). Two-tailed P values were calculated using paired t-tests to compare the means of patient 
values for eos/hpf, endoscopy, histology and symptom scores before and after budesonide therapy. 
Two-tailed unpaired t-tests were utilized in order to compare variables grouped by responders 
versus non-responders. Correlation between symptoms, endoscopy score, and peak eosinophil count 
were calculated using Spearman correlation coefficient. Results with P values <0.05 were 
considered statistically significant. Both mean and median statistics were generated, both were 
equivalent, and mean statistics are presented. Data were given as mean±SD and as median (and 
ranges). 
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RESULTS 
During the study period, 51 patients were screened. Five were excluded because of one or more 
exclusion criteria, while 10 had a positive response to the 8-week PPI therapy and were considered 
as PPI-REE. 
Thirty-six patients were enrolled (21 males, 15 females, age 12.3 7.3; disease duration: 16.8 11.4), 
17 (47%) were diagnosed in the latest 3 months prior the enrolment, while 19 (53%) had an 
established diagnosis with different previous treatments. Of these nineteen with an established 
diagnosis, 16 have been previously treated with fluticasone for 3 months, but only 10 have had a 
complete histological response. All clinical information are summarized in Table 2.  
The PVB suspension significantly reduced the median peak eosinophil count/HPF from baseline 
(42.2; range: 15-100) to 12 weeks (2.9; range: 0-30) (p<0.01). Thirty-two patients (88,9%) had a 
complete histological response and were considered as “responders”, while 2 as “partial 
responders”. Only two patients (5,5%) were non-responders, presenting more than 20 
eosinophils/hpf as well as an incomplete reduction of symptoms after OVB treatment. Of these two 
patients, one had received a specific elimination diet and the other systemic steroids. Seven of 36 
children (19,4%) had a positive MII-pH and were also treated with proton pump inhibitors. 
All patients stopped PVB therapy after 12-week period, but 2 non-responders continued PVB 
combined with other treatment (diet and/or short courses of systemic steroids), due to the presence 
of severe symptoms. After 24 weeks of follow-up, the median value of peak eosinophil count/HPF 
was 20.8 (range: 0-70), with a significant increase from 12-week value (p<0.05). Only 15 patients 
of 32 responders maintained a peak intraepithelial eosinophils count below 6 (46.7%) (9 completely 
eosinophil-free, 25%), while 13 showed a significant increase, and the remaining 4 a partial 
increase (Figures 2, 3). The two non-responders showed a mild improvement in symptoms but not 
in the eosinophil count. In the majority of our patients (9) the relapse started from the distal part of 
the esophagus, but there was no statistically significant difference from those with a relapse in the 
mid or proximal part. 
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Only 21 patients were positive at RAST/SPT tests. Seventeen were either positive at RAST and 
SPT, while 4 had only RAST positivity. The most common antigen was cow’s milk 8/21 (38%), 
followed by egg 6/21 (33%), fish 4/21 (19%), soy 4/21 (19%) and wheat 3/21 (14%). Fifteen (71%) 
had also a sensitization to environmental allergens. No correlation was found between response to 
budesonide, tendency to relapse, and positivity at RAST/SPT. 
The new PVB suspension was able to evidently improve the clinical symptom score from 3.25 
(range: 0-9) to 1.53 (range: 0-7) after 12 weeks of therapy (p<0.01). This statistical improvement 
was roughly unaltered after the treatment free period (1.72; range: 0-8) with no significant 
difference from the 12-week value (Figure 4-A). Interestingly, at baseline 11 of 36 patients were 
completely asymptomatic (clinical symptoms score=0), despite evidence of active disease at 
histology, as well as 10 patients at the end of study. Symptoms poorly correlated with peak 
eosinophil count and disease activity throughout the study (r < 0.5). 
The endoscopy score significantly decreased from 4.94 (range: 0-9) to 1.22 (range: 0-6) after 12 
weeks (p<0.01), but noticeably increased to 2.67 (range: 0-9) (p<0.05) at the end of study (Figure 4-
B). At the enrolment, 3 patients had no clear lesions at endoscopic examination, as well as 4 at the 
end of study. The endoscopic appearance weakly correlated with values of peak eosinophil count 
(0,1< r < 0,67). 
Finally, the histology score changed from 10.28 (range: 4-16) to 1.31 (range: 0-14) and to 6.03 
(range: 0-18), at 12 and 36 weeks respectively (p<0.01) (Figure 4-C). A complete histologic 
remission (histology score = 0) was observed in 28 patients after the OVB treatment, but only in 9 
at the end of study. 
No patient reported serious adverse events. A suspected oral candida occurring in one patient was 
not confirmed at the follow-up. Oesophageal candida was not detected at the endoscopy follow-ups 
in any patient. 
There was no significant difference between pre-/post treatment morning cortisol levels, 12.3 ug/dl 
(range: 4.2–22) and 10.3 ug/dl (range: 4.4 –16), respectively as well as at the end of the study 11.3 
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ug/dl (range 4.1-18). There were no clinically significant drug-related effects on values for heart 
rate or temperature, or clinically important differences or trends for changes in mean height or 
weight. All patients were considered completely adherent at the end of treatment, with 97% (range 
95-105) of the expected amount of medication consumed during the 12 weeks.  
 
DISCUSSION 
This pilot study confirms the efficacy of a new PVB suspension in treating children with active EoE 
for 12 weeks. This PVB formulation was successful in inducing symptomatic, endoscopic and 
histologic remission in children with proven EoE.  
According to the current ESPGHAN guidelines, histologic remission is one of the treatment end 
points in EoE. Indeed, our primary end point was a decrease in the peak eosinophil count to less 
than 20 cells/hpf, which is consistent with the widely agreed definition of histologic treatment end 
point (7). We were able to reach an excellent histologic remission in 89% of children treated with 
our PVB formulation; furthermore, including also the two partially responders subjects, 
oesophageal eosinophilia was found to improve in 94% of cases. Of the 2 non-responders, one 
showed a 50% reduction in oesophageal eosinophil count, while the remaining did not show any 
eosinophilic reduction and received systemic steroids in addition to topical therapy afterwards. This 
confirms that not all patients respond to steroids and this may be somewhat genetic rather than due 
to noncompliance. Indeed, Butz at al found that nonresponders had genetic evidence of steroid 
resistance with genetic transcript patterns predictive of unresponsiveness (14). 
It is worth noting that at the 24-week follow up after stopping PVB, only 46,7% and 11,1% 
remained in complete or partial histologic remission, respectively. These data are similar to those 
previously described (15). In EoE patients responding to the induction phase, eosinophilic 
recurrence is seen frequently after discontinuation of therapy and maintenance therapy may be 
needed. Indeed, since EoE is comparable to asthma of the upper gastrointestinal tract – it is 
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conceivable that patients with EoE may need a maintenance low dose steroid therapy following the 
induction (16).  
Interestingly, PVB promoted marked reduction in intensity and severity of symptoms that remained 
in a high proportion of our patients after 36 weeks. Regrettably, the correlation between symptoms 
and oesophageal eosinophilia seemed to be poor (r < 0,5) and some patients with high eosinophil 
counts may be entirely asymptomatic at diagnosis and/or after treatment. Eleven children were 
asymptomatic before budesonide therapy despite persisting esophageal eosinophilic infiltration, as 
well as 10 patients at the end of therapy. As previously reported, our data confirm that endoscopic 
or histologic remission can be hardly identified on symptoms alone (17): this suggests that 
assessment of disease severity should not rely on symptoms, while untreated subclinical 
eosinophilic inflammation can lead to stricture formation (18). 
Endoscopy was able to accurately identify disease activity in the majority of our children, in few 
cases it did not reveal abnormal features, despite presence of oesophageal eosinophilia. This study 
confirmed that endoscopy is not yet completely sufficient to accurately evaluate oesophageal 
eosinophilia (0,1< r < 0,67), thus making histology always mandatory (19). Indeed, it is known that 
children with EoE may exhibit more commonly than adults either a normal-appearing oesophagus 
or findings of plaques or edema (20). 
The histology score was also improved on PVB therapy. Despite the oesophageal epithelium is the 
main parameter of EoE activity, it is always important to consider the concurrent improvement of 
other histopathologic findings (eosinophilic degranulation, eosinophil microabscesses, basal layer 
hyperplasia dilated intracellular spaces or spongiosis, and lamina propria fibrosis) in order to have 
more information about histologic remission. Indeed, when the peak eosinophilic count is normal or 
borderline, only a complete histological examination might be able to evaluate disease activity 
improvements (21).  
Notably, the use of this PVB, which is ready-to-use, without any specific request before the 
administration and specifically designed for oesophageal therapy increased adherence (>97% in this 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
study) and feasibility of topical steroids, and it may expand the availability of this type of drug with 
a specific focus on EoE. Indeed, because no corticosteroids expressly developed for EoE have been 
approved by the European Regulatory Agency for drugs, current options are limited to swallowing 
aerosolized or nebulizer corticosteroid formulations. Usually, budesonide inhalation suspension 
either is mixed with sucralose to create a viscous preparation (11,13,22) or is nebulized and 
swallowed (11,23). As mentioned, OVB formulation is usually preferred due to higher efficacy; 
however, parents are often reluctant to a large consumption of sweeteners such as sucralose, 
maltodextrin and glucose. Although, the latter are generally considered as harmless products, a 
toxicology study in animals suggested that they could increase levels of cytochrome CYP3A4 and 
CYP2D, increase the fecal pH, cause mild depletion of goblet cells, and decrease colonic 
colonization of anaerobes (24). Despite these results have been disputed (25,26), and no clear 
evidence is yet available about the harmfulness of sucralose in humans, the development of new 
pre-prepared suspension of OVB, like the product used in this trial, is urgently warranted. 
Our study confirms previous results of placebo-controlled trials on EoE treatment with topical 
corticosteroids (13,23,27-29). However, we used a higher dosage than previous reported as 
suggested by the current guidelines. Only one paediatric study evaluated the efficacy and safety of a 
high dose of OVB in EoE, showing a marked both histologic and symptom response compared to 
placebo (12). However, the optimal dose of OVB in children with EoE has not been formally 
assessed (7). In this pilot study we tested a higher dose also on the basis of the manufacturer’s 
instruction with the objective to cover the entire oesophageal surface. Obviously, in the next future 
it will be of critical interest to evaluate the efficacy of this new preparation at lower dosage and to 
find the minimal effective dose. Moreover, since the role of a concomitant reflux disease has not 
been defined in depth, all patients with positive results at MII-pH evaluation before the enrolment 
have received concomitant PPI therapy, in order to reduce the potential effect of GERD on 
oesophageal eosinophila. 
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Remarkably, no significant changes in cortisol levels were reported in this study, even with this 
greater dosage. However, due to the controversial data on the adrenal function suppression, we 
would suggest monitoring both for adrenal suppression and other corticosteroid-associated side 
effects when treating EoE children with topical corticosteroids, especially if therapeutic program 
includes longer duration and higher dosages than traditional regimens (30-32).  
Undoubtedly, this study has several limitations. We did not design the study in a randomized 
fashion and a placebo arm was not included, differently from the majority of previous studies on 
topical steroids in adults and children (11-14). However, while OVB formulation has repeatedly 
shown to be superior to placebo, this was a pilot study based on a novel PVB formulation. 
Moreover, different concerns are currently rising in the scientific community about the use of 
placebo in paediatric chronic diseases. Indeed, recently, 4 organizations provided a joint statement 
on the role of placebo in paediatric inflammatory bowel disease trials, declaring that it should be 
avoided when the active treatment has been proven to be effective in prior large trials in adults, 
supported by clinical experience in children (33). This statement might also be accepted for EoE, 
due to similar behaviours and the risk of complications in untreated patients.  
Another limitation was a lack of a standardized validated symptom score to evaluate clinical 
response, however this concerns several others randomized, placebo-controlled studies in children 
and adults (12-13, 23-26).  
Moreover, neither histology nor endoscopy score were blinded. Nevertheless, it is also true that one 
single operator performed all the endoscopies and a single pathologist evaluated all the histological 
examinations (pre- and post- treatment). This reduced as much as possible the variability in the 
evaluations. Obviously, future studies will require a blinded evaluation with an inter-observer 
agreement calculation. 
 
In conclusion, this study showed that this new pre-prepared OVB suspension is an effective and 
safe treatment for children with proven EoE. It may have advantages over other therapies in that it 
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is palatable, practical to use, and its volume (5– 10 mL) provides pan-oesophageal mucosal 
coverage. Obviously, larger controlled clinical trials would provide more information about dosing, 
efficacy, and long-term safety of this new formulation designed specifically for the oesophagus. 
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Figure Legend 
Figure 1. The flow-chart of the study  
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Figure 2. Comparison of peak eosinophil count pre- and post- treatment with the new suspension of 
oral viscous budesonide. 
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Figure 3. Percentage of responders after 12-week treatment and at 36-week follow-up.  
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Figure 4. Median values and IQR of symptom score (A), endoscopy score (B) and histology score 
(C) during the study period, *p<0.01. 
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Table 1. Clinical symptom score 
SYMPTOMS SCORE (0-14) 
 0 = Absent 1 = Mild symptoms 
(Intermittent or not 
interrupt daily 
activities) 
2 = Severe symptoms 
(every day or interrupted 
daily activities) 
Regurgitation/heartburn    
Abdominal pain    
Nausea/vomiting    
Anorexia/early satiety    
Dysphagia    
Symptom induced 
nocturnal wakening 
   
Gastrointestinal bleeding    
  
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
Table 2. Patients demographics and clinical information 
PATIENTS N=36 
Median age, y (range) 
Gender (M, F) 
12 (5 – 18) 
21, 15 
Height  
 < 150 cm 
 ≥ 150 cm 
 
16    (46%) 
20    (56%) 
New diagnosis 
Disease duration, m, median (ranges) 
Age at diagnosis, y, median (ranges) 
17    (47%) 
14.3 (1 – 36) 
10.8 (4 – 17) 
Previous medications, n (%) 
    Corticosteroids (any) 
    Antihistamines 
    Leukotriene antagonists 
    Diet 
 
16 (44%) 
11 (31%) 
12 (33%) 
14 (39%) 
Allergy, n (%) 
    Family history 
    RAST/Skin Prick test 
    Patch Atopy test 
 
16 (44%) 
21 (50%) 
4   (11%) 
 
